DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07092605

Enrolling by invitationPhase EARLY_1

Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures

Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures: For Use in Healthy Individuals Ages 18-65 Who Seek to Improve Their Health and Longevity Through Low-dose (Microdosed) GLP1 Receptor Agonists

Lead sponsor

AgelessRx

Asset

Semaglutide

GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

150

estimated

Study population

Healthy volunteers

Key I/E criterion

•BMI ≥20

Primary endpoints

•Self-reported pain levels•Concentration of complete blood cells, as a measure of immunological health•Concentration of basic metabolites, as a measure of immunological health

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07092605
Org study IDALRx010

Timeline

Milestones

Study start2024-11-01actual
Study first posted2025-07-30actual
Last update posted2025-07-30actual
Primary completion2025-11-01estimated
Study completion2025-12-01estimated

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Healthy volunteers

Eligibility

Who can enroll

Minimum age18 Years
Maximum age65 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

•New or existing AgelessRx patient
•Adults (aged 18-65)
•Any sex
•Any ethnicity
•BMI ≥ 20 kg/m^2
•Interest in taking microdoses of semaglutide for health and longevity improvement with no intent to seek weight loss improvement.

Exclusion criteria

•Individuals who are denied a longevity product by the AgelessRx medical team will not be asked to participate in any product specific test(s) or questionnaire(s)
•History of bariatric surgery
•Use of other weight-loss medications currently or within the past 6 months
•Contraindications to semaglutide
•Significant psychiatric illness that may affect participation
•Pregnant or breastfeeding individuals

Endpoints (12)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiometabolic biomarkers
4
Other clinical outcomes
3
Patient-reported / QoL
2
Other (unclassified)
2
Glycemic / diabetes
1

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint

Variation in concentration of metabolic health biomarkers in participants microdosing GLP1s

Time frame:6 months

HbA1c, % change

percent change from baseline, improvement

LOINC 4548-4

Cardiometabolic biomarkers

4 endpoints
Primary/protocol endpoint

Change in heart rate variability in participants microdosing GLP1s

Time frame:6 months

percent change from baseline, improvement

Secondary/protocol endpoint

Variation in concentration of metabolic health biomarkers in participants microdosing GLP1s

Time frame:6 months

LDL-C, change

percent change from baseline, improvement

LOINC 13457-7

Secondary/protocol endpoint

Variation in concentration of metabolic health biomarkers in participants microdosing GLP1s

Time frame:6 months

HDL-C, change

percent change from baseline, improvement

LOINC 2085-9

Secondary/protocol endpoint

Variation in concentration of metabolic health biomarkers in participants microdosing GLP1s

Time frame:6 months

Triglycerides, change

percent change from baseline, improvement

LOINC 2571-8

Patient-reported / QoL

2 endpoints
Primary/protocol endpoint

Change in self-reported pain levels in participants microdosing GLP1s

Time frame:6 months

change from baseline, improvement

Primary/protocol endpoint

Change in mood in participants microdosing GLP1s

Time frame:6 months

SF-36 mental

percent change from baseline, improvement

Other clinical outcomes

3 endpoints
Primary/protocol endpoint

Changes in sleep patterns in participants microdosing GLP1s

Time frame:6 months

ratio, improvement

Primary/protocol endpoint

Change in frequency of physical activity in participants microdosing GLP1s

Time frame:6 months

percent change from baseline, improvement

Primary/protocol endpoint

Change in frequency of physical activity in participants microdosing GLP1s

Time frame:6 months

percent change from baseline, improvement

Other (unclassified)

2 endpoints
Primary/protocol endpoint/low confidence

Concentration of complete blood cells, as a measure of immunological health, in participants microdosing GLP1s

Time frame:6 months

percent change from baseline, descriptive

Primary/protocol endpoint/low confidence

Concentration of basic metabolites (cholesterol, glucose, creatinine, sodium, potassium), as a measure of immunological health, in participants microdosing GLP1s

Time frame:6 months

descriptive

Publications (3)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.